NICE backs Roche's MabThera in rare autoimmune disease PMLiVE The draft guidance overturns an earlier decision made by NICE which failed to recommend the use of MabThera (rituximab) for NHS use in England and Wales to treat anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis – an inflammation of the ... Roche's MabThera now favoured by NICE in vasculitis |
